期刊文献+

病原体:驱动了MHC多样性 被引量:1

Do Pathogens Drive MHC Diversity
下载PDF
导出
摘要 主要组织相容性复合体(major histocompatibility complex,MHC)因其在免疫系统中的重要作用而受到越来越多的关注。人类的MHC称人白细胞抗原(human leukoecyte antigen,HLA)系统,是迄今所知在人类基因组中最复杂的遗传多态性系统。目前的研究认为病原体是驱动和维持MHC高度多样性的主要选择压力,该文就这一领域的研究进展作一综述。 For the importance in the immune system,the major histoeompatibility complex(MHC) has been paid more and more attention. In human,MHC known as the human leukoeyte antigen(HLA) region is the most polymorphic gene cluster in human genome. The purpose of this paper is to review the evidence for the role of pathogens in the drive and maintenance of MHC polymorphism.
出处 《国际遗传学杂志》 CAS 2007年第5期365-368,共4页 International Journal of Genetics
基金 美国中华医学基金会(CMB)资助项目(04-805)
关键词 主要组织相容性复合物 多态性 病原体 选择 The major histocompatibility complex(MHC) Polymorphism Pathogen Selection
  • 相关文献

参考文献26

  • 1Anthony Nolan Research Institute-HLA Informatics Group [http:// www. anthonynolan. org. uk/HIG/index, html].
  • 2Meyer D, Thomson G. How selection shapes variation of the human major histocompatibility complex: a review, Ann Hum Gement, 2001, 65: 1-26.
  • 3Ohta T. Effect of gene conversion on polymorphic patterns at major histocompatibility complex loci. Immunol Rev, 1999,167:319-325.
  • 4Penn DJ, Fisher S. Sniffing out genetic compatibility. Biologist,2004, 51:207-211.
  • 5Bernatchez L, Landry C. MHC studies in nonmodel vertebrates: what have we learned about natural selection in 15 years? J Evol Biol, 2003,16:363-377.
  • 6Sommer S. The importance of immune gene varibility (MHC) in evolutionary ecology and conservation. Front Zool,2005,20:16.
  • 7Zinkernagel RM, Doherty PC. Immunological surveillance against altered self components by sensitised T lymphocytes in lymphyocytic choriomeningitis. Nature, 1974,251 : 547 -548.
  • 8Prugnolle F, Manica A, Charpentier M ,et al. Pathogen-driven selection and wordwide HLA class I diversity. Curr Biol,2005,15:1022-1027.
  • 9Wegner KM, Kalbe M, Schaschl H, et al. Parasites and individual major histocompatibility complex diverslty-arptimal choice? Microbes Infect. 2004,6 : 1110-1116.
  • 10Carrington M, Nelson Gw, Martin MP, et al. HLA and HIV-1:heterozygote advantage and B * 35-Cw * 04 disadvantage. Science, 1999,283 : 1748-1752.

同被引文献27

  • 1黄小琴,褚嘉祐,林克勤,陶玉芬,俞建昆,史磊,史荔,于亮,石铁流.建立不同民族永生细胞株质量控制方法的探讨[J].中国优生与遗传杂志,2005,13(9):10-13. 被引量:11
  • 2Michael NL, Nelson JA, Kewalramani VN, et al. Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodefieiency virus type 1 from a subject homozygous forCCR5 delta32. J Virol, 1998,72 : 6040-6047.
  • 3Baron B, Schembri-Wismayer P. Using the distribution of the CCR5-Delta32 allele in third-generation Maltese citizens to disprove the Black Death hypothesis. Int J Immunogenet, 2011, 38,139-143.
  • 4Hutter G, Ganepola S. The CCR5 -delta32 polymorphism as a model to study host adaptation against infectious diseases and to develop new treatment strategies. Exp Biol Med (Maywood), 2011,236 : 938-943.
  • 5Lederman MM, Penn-Nicholson A, Cho M, et al. Biology of CCR5 and its role in HIV infection and treatment. JAMA,2006, 296:815-826.
  • 6Samson M, Libert F, Doranz BJ, et al. Resistance to HIV 1 infection in caucasian individuals bearing mutant alleles of the CCR-5 ehemokine receptor gene. Nature, 1996,382 : 722-725.
  • 7Deng H, Liu R, Ellmeier W, et al. Identification of a major co- receptor for primary isolates of HIV-1. Nature, 1996,381: 661- 666.
  • 8Smith MW, Dean M, Carrington M, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study ( HGDS ), Multicenter AIDS Cohort Study ( MACS ), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science, 1997, 277,959- 965.
  • 9Martinson JJ, Chapman NH, Rees DC, et al. Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet, 1997,16-100 103.
  • 10Wang FS, Hong WG, Cao Y, et al. Population survey of CCR5 delta32, CCR5 m303, CCR2b 64I, and SDF1 3' A allele frequencies in indigenous Chinese healthy individuals, and in HIV-l-infected and HIV-l-uninfected individuals in HIV-1 risk groups. J Acquir Immune Defie Syndr, 2003,32: 124-130.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部